Close Menu

NEW YORK – Exact Sciences said on Tuesday morning that it has entered into a definitive agreement to acquire liquid biopsy test developer Thrive Earlier Detection for cash and stock consideration of up to $2.15 billion. Exact also said that it has acquired DNA methylation analysis company Base Genomics for $410 million.

Exact also reported that its third quarter revenues increased 87 percent year over year, largely in part to COVID-19 testing revenue, and announced an approximately $869 million direct-to-market stock offering.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.